Grifols S.A. (GRF) - Total Liabilities
Based on the latest financial reports, Grifols S.A. (GRF) has total liabilities worth €12.17 Billion EUR (≈ $14.23 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Grifols S.A. equity growth rate to track the company's year-over-year net asset growth rate.
Grifols S.A. - Total Liabilities Trend (2005–2024)
This chart illustrates how Grifols S.A.'s total liabilities have evolved over time, based on quarterly financial data. See GRF cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Grifols S.A. Competitors by Total Liabilities
The table below lists competitors of Grifols S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €874.70 Million |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs13.57 Billion |
|
Isupetasys
KO:007660
|
Korea | ₩533.31 Billion |
|
Spirit Aerosystems Holdings Inc
NYSE:SPR
|
USA | $10.62 Billion |
|
Sotera Health Co
NASDAQ:SHC
|
USA | $2.61 Billion |
|
China National Software & Service Co Ltd
SHG:600536
|
China | CN¥4.74 Billion |
|
AP Memory Technology Corp
TW:6531
|
Taiwan | NT$3.56 Billion |
|
Blue Owl Technology Finance Corp.
NYSE:OTF
|
USA | $5.35 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Grifols S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GRF company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Grifols S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Grifols S.A. (2005–2024)
The table below shows the annual total liabilities of Grifols S.A. from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €12.80 Billion ≈ $14.96 Billion |
-4.98% |
| 2023-12-31 | €13.47 Billion ≈ $15.75 Billion |
+3.00% |
| 2022-12-31 | €13.08 Billion ≈ $15.29 Billion |
+17.95% |
| 2021-12-31 | €11.09 Billion ≈ $12.96 Billion |
+29.60% |
| 2020-12-31 | €8.55 Billion ≈ $10.00 Billion |
-1.63% |
| 2019-12-31 | €8.70 Billion ≈ $10.17 Billion |
+11.78% |
| 2018-12-31 | €7.78 Billion ≈ $9.10 Billion |
+6.78% |
| 2017-12-31 | €7.29 Billion ≈ $8.52 Billion |
+13.82% |
| 2016-12-31 | €6.40 Billion ≈ $7.48 Billion |
+1.61% |
| 2015-12-31 | €6.30 Billion ≈ $7.37 Billion |
+8.87% |
| 2014-12-31 | €5.79 Billion ≈ $6.77 Billion |
+54.98% |
| 2013-12-31 | €3.73 Billion ≈ $4.37 Billion |
-0.34% |
| 2012-12-31 | €3.75 Billion ≈ $4.38 Billion |
-9.56% |
| 2011-12-31 | €4.14 Billion ≈ $4.84 Billion |
+250.61% |
| 2010-12-31 | €1.18 Billion ≈ $1.38 Billion |
+9.54% |
| 2009-12-31 | €1.08 Billion ≈ $1.26 Billion |
+54.32% |
| 2008-12-31 | €698.96 Million ≈ $817.16 Million |
+25.85% |
| 2007-12-31 | €555.40 Million ≈ $649.32 Million |
+1.85% |
| 2006-12-31 | €545.32 Million ≈ $637.54 Million |
-28.78% |
| 2005-12-31 | €765.74 Million ≈ $895.23 Million |
-- |
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more